Surbhi Sidana, MD

Surbhi Sidana, MD, discusses the ongoing trials that could expand the use of iberdomide into various combinations and settings in patients with multiple myeloma.

Surbhi Sidana, MD, discusses the key aspects of iberdomide that make the CELMoD's FDA approval so significant for multiple myeloma treatment.

Surbhi Sidana, MD, discusses the versatility of iberdomide and the approved Iber-Dd regimen in relapsed multiple myeloma.

In an interview, Surbhi Sidana, MD, explores the significance of iberdomide's FDA approval and how this agent fits into the growing array of novel multiple myeloma therapies.

Surbhi Sidana, MD, discusses updates from the CARTITUDE-4 study assessing the CAR T therapy cilta-cel in patients with multiple myeloma.